IDL Diagnostics AB (IDLDX) Fair Value & Analysis
Healthcare · Market cap 113M SEK
Fair value as of: Jul 16, 2026
From 1 valuation models · updated today
Fair value updated Jul 16, 2026 — revised from kr 1.93 to kr 0.1200 (−93.8%) since Jun 24, 2026. Share price −14.4% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 0.2590 – kr 0.5760 · fair‑value band kr 0.0800 – kr 0.1500 · the kr 0.4030 price screens above the kr 0.1200 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
IDL Diagnostics AB (IDLDX) currently trades at kr 0.4030, while our model-based Fair Value estimate is kr 0.1200 — implying the stock looks roughly 70.2% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, IDL Diagnostics AB generated revenue of 54.5M SEK at a net margin of -15.4%. Revenue grew 9.3% year over year. It earns a return on equity of -6.5%. The balance sheet holds a net cash position of 23.3M SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 0.0800 (bear case) to kr 0.1500 (bull case); at kr 0.4030, the current price sits above that range. The share trades about 31% below its 52-week high and 61% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside — at -70%, IDLDX screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
IDL Diagnostics AB reported revenue of kr 53.1M in FY2025 versus kr 12.0M in FY2021, a compound +45.1%/yr. Reported net income was −kr 12.2M in FY2025.
Is IDLDX fairly valued? → Check now
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | 8,423 MXN | 3,691 MXN | -56% |
| Danaher Corporation DAP | €160.60 | €75.98 | -53% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
| Agilent Technologies, Inc A | $131.62 | $60.93 | -54% |
| Waters Corporation WAT | $363.18 | $113.71 | -69% |
| IQVIA Holdings IQV | $182.17 | $119.25 | -35% |
| Natera, Inc NTRA | $228.80 | $24.55 | -89% |
| Mettler-Toledo International Inc MTD | $1,133 | $484.94 | -57% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is IDL Diagnostics AB (IDLDX) undervalued?
What is the fair value of IDLDX?
What is the quality score of IDLDX?
What is the revenue of IDL Diagnostics AB (IDLDX)?
What is the net profit margin of IDLDX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Tell me when IDL Diagnostics AB reaches its Fair Value
Just your email — and we'll notify you when the price and Fair Value of IDL Diagnostics AB materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.